National Pension Service Lowers Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

National Pension Service lowered its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 77.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 88,807 shares of the medical equipment provider’s stock after selling 304,669 shares during the quarter. National Pension Service’s holdings in Zimmer Biomet were worth $7,986,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of ZBH. Key Financial Inc boosted its position in Zimmer Biomet by 164.6% during the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 163 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new position in Zimmer Biomet during the fourth quarter worth approximately $32,000. Grove Bank & Trust boosted its position in Zimmer Biomet by 431.6% during the fourth quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 328 shares in the last quarter. Headlands Technologies LLC purchased a new position in Zimmer Biomet during the second quarter worth approximately $37,000. Finally, Basepoint Wealth LLC purchased a new position in Zimmer Biomet during the fourth quarter worth approximately $38,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Buying and Selling

In related news, SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total transaction of $250,849.00. Following the transaction, the senior vice president owned 10,224 shares in the company, valued at approximately $967,803.84. This trade represents a 20.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 1.28% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock opened at $82.83 on Tuesday. Zimmer Biomet Holdings, Inc. has a one year low of $79.12 and a one year high of $108.29. The company has a market cap of $16.02 billion, a price-to-earnings ratio of 21.51, a PEG ratio of 1.90 and a beta of 0.48. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73. The business’s 50 day moving average price is $87.82 and its 200 day moving average price is $90.61.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The firm had revenue of $2.09 billion for the quarter, compared to the consensus estimate of $2.07 billion. During the same quarter last year, the business posted $1.81 earnings per share. The firm’s revenue was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.48 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be given a dividend of $0.24 per share. The ex-dividend date is Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a yield of 1.2%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 24.94%.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Wells Fargo & Company lowered their price target on Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 29th. Citizens Jmp lowered their price target on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating on the stock in a research report on Wednesday, April 29th. Canaccord Genuity Group set a $83.00 price target on Zimmer Biomet in a research report on Wednesday, April 29th. Citigroup decreased their target price on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a research report on Thursday, May 28th. Finally, Leerink Partners started coverage on Zimmer Biomet in a research report on Monday, April 13th. They issued a “hold” rating and a $101.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus target price of $102.70.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.